DaVita HealthCare Partners (NYSE:DVA) Director Carol Anthony Davidson sold 4,038 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $79.93, for a total value of $322,757.34. Following the sale, the director now directly owns 7,290 shares of the company’s stock, valued at approximately $582,689.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

DVA has been the subject of a number of recent research reports. Robert W. Baird upgraded DaVita HealthCare Partners from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $75.00 to $95.00 in a research note on Monday, April 27th. Vetr upgraded DaVita HealthCare Partners from a “sell” rating to a “hold” rating and set a $86.75 target price on the stock in a report on Thursday, April 30th. Zacks upgraded DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $92.00 price target on the stock in a report on Friday, May 8th. Susquehanna reissued a “neutral” rating and issued a $82.00 target price (up previously from $75.00) on shares of DaVita HealthCare Partners in a research note on Saturday, May 9th. Finally, Piper Jaffray raised their price target on DaVita HealthCare Partners from $87.00 to $88.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Six research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. DaVita HealthCare Partners currently has a consensus rating of “Hold” and a consensus target price of $85.20.

Shares of DaVita HealthCare Partners (NYSE:DVA) traded up 0.10% during midday trading on Wednesday, reaching $80.08. The company had a trading volume of 1,161,425 shares. The stock has a market capitalization of $17.26 billion and a PE ratio of 38.72. The stock’s 50 day moving average is $79.75 and its 200-day moving average is $80.16. DaVita HealthCare Partners has a 12-month low of $71.50 and a 12-month high of $85.17.

DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.95 earnings per share for the quarter, meeting the consensus estimate of $0.95. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.37 billion. DaVita HealthCare Partners’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the company posted $0.95 earnings per share. On average, equities research analysts predict that DaVita HealthCare Partners will post $3.76 earnings per share for the current fiscal year.

DaVita HealthCare Partners Inc. consists of two offices, Kidney Care and HealthCare Partners (NYSE:DVA). Kidney Care is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD). Kidney Care section develops innovative clinical care, offers integrated treatment plans, well-being and personalized care teams -management services. As of December 31, 2014, we supplied dialysis and administrative services in the U.S. through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of about 173,000 patients. HealthCare Partners office is a patient- and physician-centered integrated health care delivery and management company. HealthCare Partners manages and runs medical groups and allied physician networks in California, Arizona, Nevada, Florida and New Mexico. As of December 2014, HealthCare Partners had about 837,000 members under its care.

Receive News & Ratings for DaVita HealthCare Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners and related companies with MarketBeat.com's FREE daily email newsletter.

...